Neoadjuvant FOLFOXIRI in a Locally Advanced Right Colon Cancer Patient: A Case Report From a Limited‐Resource Setting
Case Reports in Oncological Medicine · 2026-01 · 2026 (1)
DOI: 10.1155/crom/5532415 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Oncological Medicine, online erschienen am 06.11.2026. Verfasst von Osama Alazka und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology Latakia University Hospital Latakia Syria. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Although upfront surgery followed by adjuvant chemotherapy is the standard of care for locally advanced colon cancer (LACC), high rates of recurrence and surgical morbidity remain significant challenges in bulky T4 tumors. Neoadjuvant chemotherapy (NAC) is gaining traction to improve downstaging and resectability. Although doublet regimens (FOLFOX/CAPOX) are established, the use of the intensive triplet regimen FOLFOXIRI in the neoadjuvant setting for nonmetastatic LACC is less common because of toxicity concerns and limited clinical data. Case Presentation A 55‐year‐old male presented with a bulky, obstructive, right‐sided colonic mass (cT4bN+M0). Given the high‐risk features and the need for significant cytoreduction in a resource‐limited setting where molecular profiling was unavailable, neoadjuvant FOLFOXIRI was initiated. After six cycles, the patient achieved an 85% reduction in tumor volume and normalization of tumor markers (CEA/CA19‐9). Despite experiencing manageable Grade 3 neutropenia and anorexia, he underwent successful R0 resection. Histopathology confirmed significant downstaging to ypT2pN0 (0/12), reflecting a near‐complete pathological response. Following four cycles of adjuvant CAPOX, the patient remains disease‐free at 1.5 years.
Conclusion
Neoadjuvant FOLFOXIRI can achieve significant downstaging in bulky tumors and facilitates R0 resection in selected high‐risk LACC patients, even in resource‐limited settings. Despite requiring careful management of treatment toxicities, triplet NAC offers exploratory, hypothesis‐generating option for first colon cancer patients with T4 primary tumors, and can be further supported with future large clinical data.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology Latakia University Hospital Latakia Syria.
- Cancer Research Center Latakia University Latakia Syria.
- Faculty of Medicine Latakia University Latakia Syria.
ORCID-Profile: Osama Alazka
Zitieren
APA
Alazka, O., Mohammad, R., Saied, H. A., Abedallaa, H., & Abedallaa, N. (2026). Neoadjuvant FOLFOXIRI in a Locally Advanced Right Colon Cancer Patient: A Case Report From a Limited‐Resource Setting. Case Reports in Oncological Medicine, 2026(1). https://doi.org/10.1155/crom/5532415
Vancouver
Alazka O, Mohammad R, Saied HA, Abedallaa H, Abedallaa N. Neoadjuvant FOLFOXIRI in a Locally Advanced Right Colon Cancer Patient: A Case Report From a Limited‐Resource Setting. Case Reports in Oncological Medicine. 2026;2026(1). doi:10.1155/crom/5532415
BibTeX
@article{Alazka2026,
author = {Alazka, Osama and Mohammad, Rita and Saied, Haya Alreem and Abedallaa, Hamza and Abedallaa, Nader},
title = {Neoadjuvant FOLFOXIRI in a Locally Advanced Right Colon Cancer Patient: A Case Report From a Limited‐Resource Setting},
journal = {Case Reports in Oncological Medicine},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/crom/5532415}
}
EUVIMED